Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Genetic biomarkers of response to venetoclax in AML

Marina Konopleva • 12 Sep 2018
SOHO 2018
Acute Myeloid Leukemia Leukemia Decitabine Venetoclax

In this video, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Marina Konopleva, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, discusses how genetic factors influence treatment outcome with venetoclax in acute myeloid leukemia (AML). She discusses how NPM1 and IDH2 mutations both lead to improved outcomes, while TP53 mutations are related to worse outcomes, in patients given venetoclax. She relates this to venetoclax resistance caused by MCL1 overexpression, and gives her predictions for the future of venetoclax in the field of AML.

More from Marina Konopleva

2:41
Advancements in AML: an update from ASH 2023
Marina Konopleva • 8 Dec 2023
1:36
The synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating AML
Marina Konopleva • 8 Dec 2023
1:03
10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML
Marina Konopleva • 8 Dec 2023
1:17
Targeting mitochondrial metabolism to eradicate MRD in AML
Marina Konopleva • 8 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals